Fresenius Kabi Launches Plerixafor Injection
Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. About the subsidiary product Plerixafor Injection Announcement of US FDA approval
Aurobindo Pharma Ltd on Tuesday said its wholly-owned arm Eugia Pharma Specialities has received a final approval from the US health regulator for its generic version of Plerixafor injection indicated for patients with certain types of cancer to prepare them for stem cell transplant. The approval granted by the US Food & Drug Administration (USFDA) is to manufacture and market Plerixafor Injection of strengths 24 mg/1.2 mL (20 mg/mL), single-dose vial, Aurobindo Pharma said in a regulatory f .. nnRead more at: nhttps://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/aurobindo-pharma-arm-gets-usfda-nod-for-plerixafor-injection/articleshow/102102608.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
Zydus' Generic Plerixafor Receives Receives Approval in the U.S.
Accord Healthcare`s Plerixafor Approved In Europe
AuroMedics Generic Plerixafor Receives Tentative Approval in the U.S.
Amneal Eu’s Generics Plerixafor Receives Approvals In US
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced positive preliminary results from its Phase 2 clinical trial of MGTA-145 plus plerixafor in patients with multiple myeloma, which were accepted for presentation at the European Hematology Association (EHA) Congress, to be held virtually June 9-17, 2021. Magenta also provided initial direction regarding the acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) patients it expects to evaluate in its planned clinical trial with MGTA-117.